Companies /Healthcare

Revolution Medicines Inc

NASDAQ: RVMD Biotechnology
$162.69
▼ $4.18 (−2.50%) today
Markets closed · 7:46pm ET

24/7 Wall St. View

RVMD at a Glance

Valuation
Market cap
$36.1B
Profitability
Revenue (TTM)
$197.6M
EPS (TTM)
$-8.92
Price
52-week range
$70 – $224
24/7 target
$315.97
Street target
$274.76

Headquartered in Redwood City, CA Fiscal year ends December NASDAQ: RVMD revmed.com

About Revolution Medicines

Revolution Medicines is a commercial-stage oncology company that discovers, develops and commercializes oral medicines for RAS-addicted cancers.

Its RAS(ON) tri-complex inhibitor platform produces drugs designed to target the active, cancer-driving state of RAS. Its first commercial product, RASONQUE (daraxonrasib), is an oral RAS(ON) multi-selective inhibitor. It was approved by the U.S. FDA in August 2026 for previously treated metastatic pancreatic adenocarcinoma, or for patients who are not candidates for multiagent therapy. The product generates net product revenue in the U.S., and a European Commission decision is pending after a positive CHMP opinion.

The company's pipeline includes:
- zoldonrasib (RAS G12D-selective)
- elironrasib (RAS G12C-selective)
- RMC-5127 (RAS G12V-selective)
- a new class of catalytic RAS(ON) inhibitors led by RM-055

These programs are being studied across multiple global Phase 3 trials in pancreatic cancer, non-small cell lung cancer and colorectal cancer.

The company is building commercial infrastructure in Europe, Canada and Japan. It partners with BeOne Medicines, which holds Asian regional rights to four clinical-stage RAS(ON) inhibitors, and runs clinical collaborations with BMS, Summit Therapeutics and Tango Therapeutics. A funding arrangement with Royalty Pharma provides additional capital. Updated

Latest Activity

RVMDRevolution Medicines
Q3 2026
EPS
-$1.90
est -$2.38+20.2%
Revenue
$198M
est $27M+622.4%

RASONQUE turned its first commercial quarter into a 622% revenue beat. Management is telling investors not to extrapolate: expanded-access transfers, pent-up demand and initial channel stocking all inflated the quarter.

Quarterly EPS — reported vs estimate

Mad Money w/ Jim Cramer 10/27/26

  • Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
  • Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
  • CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
  • Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.

RVMD Coverage

Frequently Asked Questions

What does Revolution Medicines do?

Revolution Medicines is a commercial-stage oncology company that discovers, develops and commercializes oral medicines for RAS-addicted cancers. Its RAS(ON) tri-complex inhibitor platform produces drugs designed to target the active, cancer-driving state of RAS.

What is the RVMD stock price target?

24/7 Wall St.'s 12-month price target for RVMD is $315.97, rated Buy. The Wall Street consensus target is $274.76. RVMD price prediction →